Understanding the genomic basis of inherited respiratory disorders can assist in the clinical management of individuals with these rare disorders. We apply whole genome sequencing for the discovery of disease-causing variants in the non-coding regions of known disease genes for two individuals with inherited respiratory disorders. We describe analysis strategies to pinpoint candidate non-coding variants within the non-coding genome and demonstrate aberrant RNA splicing as a result of deep intronic variants in DNAH11 and CFTR. These findings confirm clinical diagnoses of primary ciliary dyskinesia and cystic fibrosis, respectively.
Introduction
Understanding the genomic basis of inherited respiratory disorders, including cystic fibrosis, can assist in the clinical management of individuals with these rare disorders and facilitate testing of at risk relatives. As a result, a number of assays have been developed and adopted in clinical practice to identify diseasecausing variation. [1] Genetic testing is undertaken in a staged manner when a diagnosis of cystic fibrosis is suspected. Initial testing involves the genotyping of a number of known disease-causing variants within a specified ethnic group, which can account for up to 95% of molecular diagnoses. [2] When this initial testing does not confirm a diagnosis of cystic fibrosis these tests are supplemented by DNA sequencing techniques to survey the protein-coding regions of genes known as a cause of inherited respiratory disease and related syndromic disorders (Table 1) . [3] For individuals with inherited respiratory disorders, whole genome sequencing provides an opportunity to determine the contribution of variation within the non-coding genome in the pathogenesis of wellstudied monogenic and heterogeneous disorders, e.g. cystic fibrosis and primary ciliary dyskinesia. These datasets are becoming readily available with the decreasing costs of DNA sequencing. However, establishing routine methods to accurately pinpoint disease-causing variation within large and complex genomic datasets is a significant complication. In this study we describe a framework for the identification of disease-causing variation in the non-coding genome from WGS. We demonstrate the clinical utility of these techniques for individuals without a genomic diagnosis from established diagnostic testing pathways for inherited respiratory disorders. Both our described cases were recruited to the 100,000 Genomes Project with single heterozygous pathogenic variants identified in an autosomal recessive disease gene through previous genetic testing (Table 1) .
Methods

Genetic testing strategies prior to whole genome analysis
Both probands were assessed systematically for disease-causing mutations in inherited respiratory disorder genes, as outlined in Table 1 .
Whole genome sequencing analysis strategies
Whole genome sequencing datasets were created through the UK 100,000 genomes project main program, using Illumina X10 sequencing chemistry. Sequencing reads were aligned to build GRCh37 of the human reference genome utilizing Issac (Aligner). Small variants were identified through Starline (SNV and small indels ≤ 50bp), and structural variants were identified utilizing Manta and Canvas (CNV Caller). Variants were annotated and analysed with the Ensembl variant effect predictor (v92) and bespoke perl scripts within the Genomics England secure research embassy. Prioritized variants were: (i) rare (<0.01%) or absent in gnomAD (available at http://gnomad.broadinstitute.org), (ii) rare (<1%) or absent within the Genomics England Pilot cohort, and (iii) within a defined genomic locus. We defined the relevant genomic loci as: CFTR (chr7:117,120,017-117,308,718, GRCh37) for proband 1, and DNAH11 (chr7:21,582,833-21,941,457, GRCh37) for proband 2.
RNA investigations
Lymphoblast cell cultures were established for a control sample and proband 1. RNA was extracted using the RNeasy® Mini Kit (Qiagen, UK, Catalogue No. 74104) following the manufacturer's protocol. RNA was extracted from whole-cell blood using the PAXgene™ Blood RNA System Kit (Qiagen, UK. Catalogue No. 762174), following the manufacturer's protocol for a control sample and proband 2. Extracted RNA was reverse transcribed using the High Capacity RNA to cDNA Kit (Applied Biosystems, UK. Catalogue No. 4387406) following the manufacturer's protocol. Gene specific primers (available on request) amplified relevant regions of CFTR and DNAH11. PCR products were visualized on an agarose gel using a BioRad Universal Hood II and the Agilent 2200 Tapestation. Visualized bands were cut out and prepared for capillary sequencing on an ABI 3730xl DNA Analyzer.
Variant Segregation
Primers were designed to amplify relevant genomic DNA regions in the probands and their unaffected relatives (both parents for proband 2 and daughter for proband 1). Amplicons were prepared for capillary sequencing using an ABI 3730xl DNA Analyzer.
Results
Clinical findings
Proband 1 ( Figure 1 ) received a late diagnosis of cystic fibrosis at 17 years old. Genetic testing described in Table 1 uncovered the common del508 mutation in CFTR in a heterozygous state. A sweat test was positive: sweat chloride 68 mmol/L (normal range = 0-39 mmol/L); sweat conductivity 92 mmol/L (normal range = 0-49 mmol/L). The proband is currently 51 years old but her disease severity has progressed and she is awaiting double lung transplant.
Proband 2 (Figure 2 ) was diagnosed in childhood with bronchiectasis, she is currently 54 years of age. Nasal nitric oxide levels were extremely low at 4 parts per billion (ppb, normal range = <25 ppb) consistent with a diagnosis of PCD. [4] Three examinations of the proband's cilia with electron microscopy (EM) showed a significant proportion of static and dyskinetic cilia (Supplementary Video), with a high ciliary beat frequency: 20.2Hz (95%CI=19.8-20.5Hz); 22.0Hz (95%CI=20.1-23.2Hz); and 20.1Hz (95%CI=19.8-20.5Hz). EM histology showed normal dynein arms and microtubules with no ciliary disorientation, and conical ciliated protrusions were observed from epithelial cells. These findings are consistent with mutations in DNAH11. [5] Genetic testing described in Table 1 identified a heterozygous nonsense mutation in DNAH11.
Identification of non-coding likely pathogenic variation from WGS
Whole genome sequencing generated 49,764 unique reads for the specified region of CFTR, achieving coverage of 30x and 10x for 91.5% and 99.3%, respectively. Similarly, 92,053 unique reads were generated for the specified region of DNAH11, achieving coverage of 30x and 10x for 89.8% and 100%, respectively. Our variant analysis strategy for WGS identified both previously identified pathogenic variants (Table 1 ). In addition, these analyses identified candidate heterozygous variants within the introns of CFTR and DNAH11 (Table 1) . DNAH11 c.6547-963 G>A. This variant has not been previously reported as a cause of disease. The variant is present as two heterozygous alleles in gnomAD (rs764374746). The variant alters the nearby sequence motif from GGGT to AGGT. Analysis with the in-silico splicing tools SpliceSiteFinder-like, MaxEntScan and Human Splicing Finder suggest that this could result in a new cryptic splice donor within this sequence motif.
CFTR c. 3874-4522 A>G. This variant has previously been reported in a single case of cystic fibrosis. [6] The variant is absent from gnomAD. In-silico splicing tools (SpliceSiteFinder-like, MaxEntScan and Human Splicing Finder) suggest that this variant may result in the introduction of a new cryptic splice acceptor site. The variant is not included in diagnostic genotyping kits and is not surveyed through protein-coding based DNA sequencing techniques.
Variant Segregation
Segregation analyses identified that DNAH11 c.8610C>G and c.6547-963G>A were in-trans in proband 2, who had inherited these variants from her unaffected father and mother, respectively (Figure 1) . Assessment of the unaffected daughter of proband 1, who had inherited p.Phe508del on a single allele, also demonstrated that CFTR c.3874-4522 A>G and p.Phe508del are in-trans (Figure 1 ).
RNA assessments for variant pathogenicity
PCR products were amplified from proband and control cDNA utilizing primers designed for exons flanking the prioritized intronic variants. Our findings show abnormal RNA splicing patterns for the probands carrying DNAH11 c.6547-963 G>A and CFTR c. 3874-4522 A>G through the introduction of cryptic splice sites (Figures 1 & 2) . Both cryptic exons are expected to result in premature termination of protein synthesis and are interpreted as pathogenic (ClinVar submission in process).
Discussion
In this study we describe the discovery of non-coding pathogenic variants from WGS as a cause of inherited respiratory disorders in two unrelated individuals. Through targeted RNA investigations we established that these prioritized variants have adverse effects on RNA expression (Figures 1 & 2) . These findings in CFTR and DNAH11 confirm clinical diagnoses of autosomal recessive cystic fibrosis and primary ciliary dyskinesia, respectively, and enable informed management and cascade testing for at risk relatives. The delineation of the underlying mutations in CFTR is an important consideration for the lifelong management for individuals with cystic fibrosis, as appropriate modulator therapies can extend life span. [7] We pinpoint mutations that directly impact RNA splicing for CFTR and DNAH11, and thereby underline the potential utility of antisense oligonucleotide therapies which target and correct aberrant splicing within pre-mRNA. [8] Both patients are in their sixth decade of life and present symptoms consistent with a milder spectrum of disease. The hypothesis that alternative splicing mechanisms retain some residual normal transcript, and thereby underpin milder phenotypic presentation, provides an interesting avenue for future investigations.
Our findings demonstrate the additional advantage of WGS over other commonly used genetic testing modalities (Table 1) . Other technologies could have uncovered the pathogenic variants discovered in this study. For example, assessment of RNA expression through mRNA sequencing [9] or targeted sequencing of intronic regions of CFTR and DNAH11. However, in addition to the discovery of novel noncoding pathogenic variation, WGS also provided a one-step tool to test and explicitly rule out other hypotheses that may be missed by these other techniques, e.g. the existence of novel structural variants and variants impacting the promoter regions of CFTR and DNAH11. Moreover, if patients are negative from these hypothesis-led assessments, then WGS datasets can lead to the discovery of new diseasecausing genes (Table 1) . [3] Our analysis strategy was guided by the clinical presentation of the recruited probands and the existence of heterozygous pathogenic variants in genes already established as a cause of inherited respiratory disorders. We demonstrate here, and previously, [10] that such strategies can be rapidly and effectively applied to WGS datasets for families with significant previous genomic testing to uncover novel genomic diagnoses. We suggest that these strategies are applied to individuals whose clinical presentation is in keeping with an autosomal recessive Mendelian disorder and previous testing of known disease genes has identified a single heterozygous pathogenic variant.
